Canadian Court Won't Shrink Paxil Birth Defect Class
A Canadian appeals court on Friday rejected GlaxoSmithKline Inc.'s efforts to significantly limit class certification on failure-to-warn issues in a suit claiming the antidepressant Paxil causes birth defects, siding with a...To view the full article, register now.
Already a subscriber? Click here to view full article